ERS 2026: Phase Ib/IIa results support further evaluation of 9MW1911 in COPD

The results add clinical support to IL-33/ST2 as a potential therapeutic axis in COPD. The results add clinical support to IL-33/ST2 as a potential therapeutic axis in COPD. Although the efficacy analysis was exploratory, 9MW1911 has earned further investigation for a broad COPD population. Credit: HobbitArt/Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise. Hard data and deep insights…

Source: Clinical Trials Arena